Tabelecleucel
Epstein-Barr Virus-Related Tumor
Atara BiotherapeuticsCell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Epstein-Barr Virus-Related Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes Atara Biotherapeutics | Phase 1/2 | CCC |
Ebv-Specific T Cells: B Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
Avelumab Yonsei University | Phase 2 | CCC |
Ebv Mrna Vaccine Sun Yat-sen University | Phase 1 | CC |
AS01 COMPONENT QS-21 Ohio State University Comprehensive Cancer Center | Phase 1 | NR |
Same molecule, other indications
Tabelecleucel is also rated in:
Epstein-Barr virus-associated lymphoproliferative disorderActive
BB
Indicative · Phase 3
66 / 100
View asset →disease related to hematopoietic stem cell transplantActive
BB
Indicative · Phase 3
66 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →